Expression of sBCMA in Newly Diagnosed Multiple Myeloma Patients and Its Relationship with Prognosis.
10.19746/j.cnki.issn.1009-2137.2023.04.027
- Author:
Lan-Lan ZHENG
1
;
Bin LI
2
Author Information
1. Department of Hematology, Hefei Eighth People's Hospital, Hefei 230011, Anhui Province, China.
2. Department of Hematology, Hefei First People's Hospital, Hefei 230061, Anhui Province, China.E-mail: ahbengbuwyl@163.com.
- Publication Type:Journal Article
- Keywords:
multiple myeloma;
prognosis;
sBCMA;
treatment outcome
- MeSH:
Humans;
Multiple Myeloma;
B-Cell Maturation Antigen/metabolism*;
Prognosis
- From:
Journal of Experimental Hematology
2023;31(4):1108-1112
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the expression level of serum B-cell maturation antigen (sBCMA) in the peripheral blood of newly diagnosed multiple myeloma (MM) patients, and explore its relationship with the prognosis of MM patients.
METHODS:The peripheral blood of 31 newly diagnosed MM patients and 30 healthy volunteers were collected. The level of sBCMA in the peripheral blood was detected by enzyme-linked immunosorbent assay (ELISA). The correlation between the level of sBCMA and the prognosis of MM patients was analyzed.
RESULTS:The level of sBCMA in newly diagnosed MM patients was significantly higher than that in healthy controls (P <0.05). The level of sBCMA was closely related to the plasma cells ratio in bone marrow, the M protein level and the treatment (P <0.05). The level of sBCMA was negatively correlated with the overall survival (OS) of MM patients (r =-0.47). MM patients with low expression of sBCMA had significantly longer OS than patients with high expression of sBCMA (P <0.05).
CONCLUSION:The level of sBCMA is significantly increased in MM patients, which is expected to be a new indicator for evaluating the curative efficacy and prognosis of MM patients. Targeting sBCMA may provide new ideas for the treatment of MM.
